Atossa Therapeutics Inc (NASDAQ: ATOS) is seeking to develop innovative medicines in oncology focusing on breast cancer.
Received HREC approval: Atossa Therapeutics Inc (NASDAQ: ATOS) recently announced that the company had received the Human Research Ethics Committee (HREC) to open or start a clinical study of AT-H201 in Australia. The AT-H201 formulation is currently developed as an inhalation therapy for patients severely affected by COVID-19 and those infected with pulmonary disease (post-infection).
Globally every nation is fighting with the COVID-19 pandemic, which is affecting the health of the masses. As per the various medical reports, many regions reported low vaccination rates and now combined with SARS – COV – 2 variants, which proved to be more deadly and infectious. Atossa Therapeutics stated that if the study is successful, they will also study the efficacy of their proprietary product AT-H201 on COVID-19 patients (moderately ill) who can be treated through a nebulizer. The company’s fundamental goal is to develop nebulized AT-H201 to improve lung function in patients that may help the patient stay away from Ventilators.
The initial study report suggested the pulmonary function changes 60 days for patients after recovering from COVID. The company is trying to develop a nebulizers that can be used or allow for treatment at home. The study has taken under four parts, including single and multiple ascending dose parts and a combination of healthy individuals and COVID-19 infected patients.
AT-H201 a proprietary combination of two drugs: The combination of drugs was previously approved by FDA. The medicine AT-H201 will be inhaled through a nebulizer to improve the functioning of the lungs for COVID-19 patients. AT-H201 study shows that the components of AT-H201 inhibit SARS – COV – 2 infections. The study stated that the effectiveness of AT-H201 is four times more effective than Remdesivir and HCQ (Hydroxychloroquine). The company will start the sale of AT-H201, post obtaining regulatory approval. However, the company can’t give any assurance whether the trial will be successful or not.